NEFAZODONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nefazodone Hydrochloride, and when can generic versions of Nefazodone Hydrochloride launch?
Nefazodone Hydrochloride is a drug marketed by Ani Pharms, Aurobindo Pharma Usa, Dr Reddys Labs Inc, Fosun Pharma, Ivax Sub Teva Pharms, Roxane, Sun Pharm Inds Ltd, Teva, and Watson Labs. and is included in nine NDAs.
The generic ingredient in NEFAZODONE HYDROCHLORIDE is nefazodone hydrochloride. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the nefazodone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nefazodone Hydrochloride
A generic version of NEFAZODONE HYDROCHLORIDE was approved as nefazodone hydrochloride by TEVA on September 16th, 2003.
Summary for NEFAZODONE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 9 |
NDAs: | 9 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Clinical Trials: | 16 |
Patent Applications: | 1,195 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEFAZODONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NEFAZODONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Instituto Nacional de Salud Publica, Mexico | Phase 3 |
Laboratorios Grossman, S.A. | Phase 3 |
James J. Peters Veterans Affairs Medical Center | Phase 2 |
Pharmacology for NEFAZODONE HYDROCHLORIDE
Drug Class | Serotonin Reuptake Inhibitor |